



COLUMBIA UNIVERSITY

*College of Physicians
and Surgeons*



International Society for
Cutaneous Lymphomas



COLUMBIA UNIVERSITY
MEDICAL CENTER

*Herbert Irving Comprehensive
Cancer Center*



3rd World Congress of Cutaneous Lymphomas

October 26-28, 2016

Alfred Lerner Hall
COLUMBIA UNIVERSITY

Chairs: Maarten Vermeer, MD, PhD & Larisa Geskin, MD

Register at www.columbiacme.org

3rd World Congress of Cutaneous Lymphomas

Columbia University | October 26-28, 2016

Preliminary program (updated August 29, 2016)

WEDNESDAY, October 26, 2016

07:00-08:30	EORTC CLTF Board Meeting		
08:30-08:45	Welcome Remarks		Martin Vermeer & Larisa Geskin
08:45-10:10	Scientific Session A. Classification & Clinical Pathology		
	<i>Chairs: Guitart, Kempf, Swerdlow, Willemze</i>		
	◊ Cutaneous Lymphomas & the 2016 WHO Classification	Steven Swerdlow	20
A-01	Studies in folliculotropic MF and transformed MF: consequences for the ISCL/EORTC staging system	Rein Willemze	15
A-02	Primary Cutaneous Aggressive Epidermatropic T-Cell Lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of Lymphomas	Joan Guitart	9
A-03	Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: Clinico-Pathological Features and Genomic Alterations	Emilio Berti	9
A-04	CD8+ mycosis fungoides: an indolent lymphoproliferative disorder	Estela Martinez-Escala	9
A-05	Unilesional mycosis fungoides is associated with increased expression of miR-17~92, Th1 cytokine profile and absence of Th2	Lilach Moyal	9
A-06	Pediatric mycosis fungoides: Clinicopathologic characteristics and outcome and a study of the human leukocyte antigen system	Emmilia Hodak	9
10:10-10:30	Break & Poster Viewing		
10:30-12:00	Scientific Session B. Pathogenesis & Apoptosis		
10:30-12:00	<i>Chairs: Gniadecki, Pujol, Wong, Wood</i>		
B-01	Introduction + Apoptotic Abnormalities in CTCL: Pathogenetic and Therapeutic Implications	Gary Wood	15
B-02	Micro RNA regulatory circuits in chemotherapy-induced apoptosis in CTCL cells	Robert Gniadecki	9
B-03	Evidence for Phospholipase C Gamma 1 (PLCG1) mutations augmenting aberrant T-cell Receptor signalling in Sézary Syndrome	Varsha M. Patel	9
B-04	A comparison of transcriptome sequencing and TOX chromatin immunoprecipitation data identifies putative downstream effects of transcription factor dysregulation in Sézary syndrome	Brittany O. Dulmage	9
B-05	Inactivation of runx3/p46 Promotes Cutaneous T-Cell Lymphoma	Chalid Assaf	9
B-06	STAT3 activation results from the epigenetic abrogation of miR-124 in Cutaneous T-cell lymphoma	Fernando Gallardo	9
B-07	Novel high-throughput virome capture sequencing technique failed to identify viral pathogens in patients with cutaneous T-cell lymphoma	Mary E. Anderson	9
B-08	Mitochondrial retrograde signaling regulates sensitivity to metabolic stress and allows selective targeting of cutaneous T-cell lymphoma	Stefan M. Schieke	9
12:00-13:00	Lunch & Poster Viewing		
13:00-14:00	Scientific Session C. Multinational Collaborative Studies		
	<i>Chairs: Scarisbrick, Quaglino, Olsen, Kim, Y</i>		
	◊ Introduction	Youn H. Kim	5
C-01	Cutaneous Lymphoma International Consortium: An Advanced Stage Prospective Study Uniting International Expert Centres to Evaluate and Validate the Prognostic Index Model	Julia Scarisbrick	8
C-02	PROspective Cutaneous Lymphoma International Study (PROCLIPI) in Early Stage Mycosis Fungoides	Julia Scarisbrick	8
C-03	Global Patterns of Care in Advanced Stage Mycosis Fungoides/Sézary Syndrome: A Multicenter Retrospective Follow-up Study from the Cutaneous Lymphoma International Consortium	Pietro Quaglino	12
C-04	Validation of Central Pathology Review in Advanced-Stage Cutaneous T-cell Lymphomas, a Multi-Institutional and International Pathology Pilot Study	Alejandro Ariel Gru	10
C-05	USCLC update	Elise Olsen	10
14:00-15:00	Scientific Session D. Epidemiology & Population Studies		
	<i>Chairs: Zhang, Knobler, Weinstock, S. Stellman</i>		
	◊ Introduction	Martin Weinstock	10
	◊ Introduction	Steven Stellman	15
D-01	The Incidence of Cutaneous T-Cell Lymphoma in The Veteran Population	Christina Del Guzzo	9
D-02	Relative frequency, clinical features, and survival outcomes of 395 patients with cutaneous lymphoma in Korea: a subgroup analysis per 10-year period	Woo Jin Lee	9
D-03	Characterization of 794 cutaneous lymphoma patients from a single center in Brazil	Denis Miyashiro	9
D-04	Cutaneous T-cell Lymphoma in Saudi population	Yousef Binamer	9

15:00-15:20 **Break & Poster Viewing**

15:20-17:00 **Scientific Session E. Immunology & Immunopathogenesis**

Chairs: Sugaya, Querfeld, O'Malley, Rook

Introduction

		Alain Rook	10
E-01	The immune checkpoint receptors ICOS and PD1 in mycosis fungoides and Sézary syndrome: correlation with disease and outcome.	Christiane Querfeld	9
E-02	Lack of support for a Th2 origin of Mycosis fungoides revealed by RNA sequencing	A.N. Bastidas-Torres	9
E-03	IL-10 is a biomarker of advanced mycosis fungoides and is required for maximal tumor formation in a murine model of CTCL	Xuesong Wu	9
E-04	Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation	Patrizia Fuschiotti	9
E-05	Dysfunctional cytokines production induced by Toll-like receptors activation in the Sézary syndrome	Kelly C Gomes Manfrere	9
E-06	TIGIT and Helios are Highly Expressed on CD4 T-Cells in Sezary Syndrome	Neha Jariwala	9
E-07	Mycosis fungoides: new issues from microenvironment	Alessandro Pileri	9
E-08	Impaired Secretion of CXCL9/MIG and CXCL10/IP-10 in Sezary Syndrome	Marina Torrealba	9
E-09	Ineffective antibody-dependent cellular cytotoxicity in patients with late stage cutaneous T cell lymphoma	Emmanuella Guenova	9
E-10	Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages	Werner Kempf	9

17:30-19:30 **Picture Taking & Welcome Reception**

3rd World Congress of Cutaneous Lymphomas

Columbia University | October 26-28, 2016

Preliminary program (updated August 29, 2016)

THURSDAY, October 27, 2016

07:00-08:00	ISCL Board of Directors Meeting		
08:00-09:30	Scientific Session F. Biomarkers		
	<i>Chairs: Stadler, Iwatsuki, Geskin, Bagot</i>		
	◊ Introduction	Martine Bagot	10
F-01	Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediating Cytotoxic Activity against Tumor Cells via CD155	Naomi Takahashi	9
F-02	Evaluation of validated DNA methylation biomarkers in early Sézary syndrome patients	Wim Zoutman	9
F-03	Variability in CD30 and other biomarkers in Mycosis Fungoides/Sézary Syndrome (MF/SS): Challenges in Tissue Biomarker Interpretation	Ziba Rahbar	9
F-04	CXCL13 and BOB1 expression in initial biopsies of mycosis fungoides with stable early stage and later tumor stage disease	Ulrike Wehkamp	9
F-05	Usefulness of KIR3DL2 to diagnose, follow-up and manage the treatment of Sézary syndrome patients	Charlotte Hurabielle	9
F-06	c-MET is overexpressed in cutaneous T-cell lymphoma and represents a potential therapeutic target	Chalid Assaf	9
F-07	Biological and clinical significance of tryptophan catalyzing enzymes in patients with cutaneous T-cell lymphoma	Liisa Väkevää	9
F-08	Cell adhesion molecule 1 is a biomarker for leukemic cells in progressive or refractory Sézary syndrome	Keiji Iwatsuki	7
F-09	A reactivation signal, BZLF-1, is a biomarker for severe phenotypes of cutaneous EBV-associated T/NK lymphoproliferative disorders	Keiji Iwatsuki	7
09:30-09:50	Break & Poster Viewing		
09:50-10:10	Plenary Session: Genomic and Mutational Landscape in T-cell Lymphomas	Adolfo Ferrando	20
10:10-10:30	Plenary Session: Epigenetics of CTCL	Martin Vermeer	20
10:30-10:35	Awards Ceremony		5
10:35-12:00	Scientific Session G. Genetics		
	<i>Chairs: Girardi, Whittaker, Ortiz Romero, Palomero</i>		
10:35-12:00	Introduction of CTCL Genomics	Teresa Palomero	10
G-01	Validation and functional interrogation of JAK and STAT variants in Primary Cutaneous T-cell Lymphoma (CTCL)	Rosie M. Butler	9
G-02	Direct gene expression measurement in skin helps predict long-term clinical outcome in patients with cutaneous T-cell lymphomas	Adele de Masson	9
G-03	Development of an in vitro CTCL platform for screening targeted molecular agents	Jason Weed	9
G-05	High-throughput T cell receptor sequencing transforms care of cutaneous T cell lymphoma patients	John O'Malley	9
G-06	TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in cutaneous T-cell lymphoma	Lanny Kirsch	9
G-07	Integrative analysis of genomic data to identify common genomic alterations in cutaneous T-cell lymphoma	Li-Wei Chang	9
G-08	Genomic landscape of Mycosis fungoides	Jinah Yoo	9
G-09	Lessons Learned From a Novel Mouse Model of CTCL	Sergei B. Koralov	9
12:00-13:30	Lunch & Poster Viewing		
12:00-13:30	EORTC CLTF Meeting		
12:30-13:30	USCLC General Meeting		
13:30-14:25	Scientific Session H. Cutaneous B-cell lymphomas		
	<i>Chairs: Hodak, Junkins-Hopkins, Guitart</i>		
	◊ Introduction	Joan Guitart	10
H-01	Immunoglobulin constant region mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	Marvyn T. Koning	7
H-02	The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis	Marvyn T. Koning	7

H-03	PD1 and PD-L1 expression in primary cutaneous diffuse large B cell lymphoma	Christina Mitteldorf	9
H-04	Primary cutaneous diffuse large B-cell lymphoma, leg-type: high frequency, diagnostic and prognostic value of MYD88 L265P mutation	Anne Pham-Ledard	9
H-05	Primary Cutaneous B-Cell Lymphoma – Systemic spread is rare whilst cutaneous relapses and secondary malignancies are frequent	Sue Ann Chan	9
14:25-14:45	Break & Poster Viewing		
14:45-15:50	Scientific Session I. Rare Cutaneous Lymphomas		
14:45-15:50	<i>Chairs: Berti, Cerroni, Rosen, Kadin</i>		
I-01	Introduction + A new look at atopy in CD30+ Cutaneous Lymphoproliferative Disorders	Marshall Kadin	15
I-02	TOX expression in cutaneous T-cell lymphomas and cutaneous B-cell lymphomas	Anne M.R. Schrader	7
I-03	No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course	Anne M.R. Schrader	7
I-04	Skin manifestations and outcome in adults with pre-B cell acute lymphoblastic leukemia; an important differential diagnosis to primary cutaneous follicle center lymphoma, diffuse type and secondary cutaneous follicular lymphoma	Yann Charli Joseph	9
I-05	Cutaneous manifestations of Adult T-cell lymphoma/leukemia. Monocentric study of 37 patients between 1996 and 2016.	Charlotte Hurabielle	9
I-06	Blastic Plasmacytoid Dendritic Cell Neoplasm: an update on cytogenetic data	Emilio Berti	9
I-07	Expression of TFH markers and detection of RHOA p.G17V and IDH2 p.R172K/S mutations in cutaneous localizations of angioimmunoblastic T-cell lymphomas	Nicolas Ortonne	9
15:50-16:00	Break		
16:00-17:00	Scientific Session J: Quality of Life & Outcomes Studies [Concurrent Session]		
16:00-17:00	<i>Chairs: McCann, Tawa, Finnegan, Zic</i>		
16:00-17:00	Introduction	John Zic	10
J-01	Cost-Effectiveness Analysis of Systemic Treatments for Cutaneous T-Cell Lymphoma	Larisa Geskin	9
J-02	Development and validation of the first measure of quality of life specific for patients with Mycosis Fungoides/Sézary syndrome	Stacey McCaffrey	9
J-03	Large prospective observational registry in MF-CTCL	Badri Rengarajan	9
J-04	Assessment of QOL, illness perception, and illness behavior in 92 patients with primary cutaneous lymphoma	Stefanie Porkert	9
J-05	Caregiver Burden and Quality of Life Factors Affecting Caregivers of Patients with Cutaneous T-Cell Lymphoma	Sue A. McCann	9
16:00-17:00	Scientific Session K. Clinical Aspects [Concurrent Session]		
	<i>Chairs: Pinter-Brown, Pittelkow, Sanches, Myskowski</i>		
◊	Introduction	Patricia Myskowski	10
K-01	Cutaneous lymphomas during anti-tumor necrosis factor therapy are often associated with misdiagnosed “psoriasis” or poorly characterized “dermatitis”	Estela Martinez-Escala	9
K-02	Poor Outcome of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study	Frederick Lansigan	9
K-03	Sézary syndrome without erythroderma	Liliane Laroche	9
K-04	Risk of venous thromboembolism in patients with parapsoriasis (early mycosis fungoides): A Danish nationwide population-based cohort study	Lise M. Lindahl	9
K-05	Protean Manifestations of Early Sézary Syndrome	Robert Gniadecki	9
16:00-17:00	Scientific Session L. Applied Research [Concurrent Session]		
	<i>Chairs: Schieke, Hwang, Koralov, Gniadecki</i>		
L-01	Introduction + An in vitro model of psoralen ultraviolet A (PUVA)-induced apoptosis of cutaneous lymphoma cell lines: Augmentation by type I interferons via JAK1-STAT1 pathway	Robert Gniadecki	15
L-02	MYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype	Marion Wobser	9
L-03	Analysis of the expression and activity of metalloproteinases 2 and 9 and their inhibitors and correlation with histological findings and prognosis in mycosis fungoides	Roberta Vasconcelos	9
L-04	Impact of immunodeficiency on outcomes and immune-checkpoint molecule expression in mycosis fungoides	Melissa Pulitzer	9
L-05	Role of PAK1 in the onset and progression of cutaneous T-cell lymphoma	Yimeng Wang	9
L-06	Doxycycline is an NF-κB Inhibitor That Induces Apoptotic Cell Death in Malignant T-cells	Brian Poligone	9
17:15-18:15	Shuttle to Dinner Cruise		
18:15-21:30	Congress Dinner Cruise		

3rd World Congress of Cutaneous Lymphomas

Columbia University | October 26-28, 2016

Preliminary program (updated August 29, 2016)

FRIDAY, October 28, 2016

07:00-08:00	USCLC Board of Directors Meeting		
08:00-10:30	Scientific Session M. Therapeutics 1a: Translational/Pre-clinical Studies		
	<i>Chairs: Zain, Papadavid, Prince, Bates</i>		
	◊ Introduction + CTCL as a disease of epigenetic dysregulation	Susan Bates	15
M-01	Novel treatment option for CTCL: Studying the effects of dimethylfumarate from bench to bedside	Jan P. Nicolay	9
M-02	Translational Development of MRG-106, an Oligonucleotide Inhibitor of miR-155, as a Novel Therapy for CTCL	Anita G. Seto	9
M-03	Chimeric Antigen Receptor Modified T cells Targeting Chemokine Receptor CCR4 as a Therapeutic Modality for T-cell Malignancies including CTCL	Marshall E. Kadin	9
M-04	Differential transcriptome response in mycosis fungoides patients following silicon phthalocyanine 4 photodynamic therapy	Sayeeda Ahsanuddin	9
M-05	Preclinical Investigation of SGN-CD70A Drug-Antibody Conjugate in T Cell Lymphomas	Wei Ai	9
M-06	Characterization of CD70 immunoperoxidase staining on cutaneous T-cell lymphomas	Laura B. Pincus	9
09:10-09:20	Quick Break and switch Chairs		
09:20-10:30	Scientific Session M. Therapeutics 1b: Translational/Pre-clinical Studies		
	<i>Chairs: Whittaker, Dummer, Pimpinelli, Bates</i>		
M-07	Synergy of romidepsin and mechlorethamine in cutaneous T-cell lymphoma	Christina C. Patrone	9
M-08	RARa/RXR Synergism Potentiates Responsiveness in Cutaneous T Cell Lymphoma	Sebastian S. DeMarco	9
M-09	AN-7 sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of double-strand break repair	Lilach Moyal	9
M-10	Resminostat - an epigenetic approach for CTCL maintenance treatment	Matthias Borgmann	9
M-11	Apoptosis induction in Cutaneous T-cell Lymphoma Cells after Treatment with Lenalidomide	E. Papadavid	9
M-12	PI3K-gamma use in CTCL	George Deng	9
10:30-10:45	Break & Poster Viewing		
10:45-11:45	Scientific Session N. Therapeutics 2: Advanced Therapies, including HSC Transplantation		
	<i>Chairs: Horowitz, Foss, Hoppe, Weng, Porcu</i>		
	◊ Introduction + Role of Allogeneic HSC Transplantation CTCL	Pierluigi Porcu	15
N-01	Long-term outcome of allogeneic hematopoietic stem cell transplantation for patients with mycosis fungoides and Sézary syndrome	Francesco Onida	10
N-02	Allogeneic Stem Cell Transplantation in Refractory MF/SS: Results with Reduced Intensity Conditioning Regimen	Francine Foss	8
N-03	Pralatrexate in Cutaneous T cell Lymphoma: Retrospective Experience with and without Leucovorin	Francine Foss	8
N-04	Low dose Total Skin Electron Beam therapy (TSEB) 12Gy in 8 # over 2 weeks. The results in 103 patients from the UK.	Stephen Lloyd Morris	10
N-05	The French Experience of Chlormethine Gel for the Treatment of Mycosis Fungoides:A Retrospective Series of 107 cases	Steve Mathieu	10
11:45-12:00	ISCL General Meeting		
12:00-13:30	Lunch & Poster Viewing		
12:00-13:30	CME SYMPOSIUM: Immunology & Immunotherapy of Cutaneous Lymphomas		
	Animal Models as a Means to Study the Tumor Microenvironment in CTCL	Sam Hwang	
	Pathogenesis of Immune Compromise in the CTCL Patient	Michael Girardi	
	Importance of the Innate Immune Response in Therapy of CTCL	Alain Rook	
	New Immunotherapies in Clinical Development	Youn H. Kim	
13:30-15:35	Scientific Session O. Therapeutics 3a: Endpoints & Clinical Trials		
	<i>Chairs: Bagot, Kim, Y, Lebwohl, Horwitz</i>		
	◊ Introduction + Landscape of new therapeutics in CL	Steven Horwitz	15
O-01	Exploring New Meaningful Endpoints for CTCL Clinical Trials in Two Phase II Studies of Brentuximab Vedotin (BV) in Patients with Mycosis Fungoides (MF) and Sézary Syndrome (SS)	Youn H. Kim	10
O-02	KIR3DL2 expression in cutaneous T-cell lymphomas: a widely-shared target	Maxime Battistella	10
O-03	First-in-Human, open label, multicenter phase 1 study of IPH4102, first-in-class humanized anti-KIR3DL2 mAb, in relapsed/refractory CTCL: preliminary safety and clinical activity results	Martine Bagot	10
O-04	E7777 Demonstrated Safety in Persistent or Recurrent Cutaneous T-Cell Lymphoma	Madeleine Ducic	10
O-05	A Single-arm Phase 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose Total Skin Electron Beam Therapy (LD-TSEBT)	Richard Hoppe	10

13:30-15:35	Quick Break and switch Chairs		
	Scientific Session O. Therapeutics 3b: Endpoints & Clinical Trials		
	<i>Chairs: Duvic, Akilov, Sawas, Feldman</i>		
O-06	Lenalidomide in relapsed or refractory primary cutaneous large B-cell lymphomas, leg-type: first results of a multicentric prospective phase II trial "REV-LEG"	Marie Beylot-Barry	10
O-07	Phase 1, Single-Arm, Open-Label, Dose Escalation Trial of Microneedle Array-Doxorubicin in Patients with Cutaneous T cell Lymphoma	Oleg Akilov	10
O-08	Interim analysis of phase II clinical trial PimToMF (Topical Pimecrolimus in early MF) Eudra CT 2014-001377-14	Pablo L. Ortiz Romero	10
O-09	Preliminary results of Phase I, anti-CD37-MMAE conjugate in CTCL (LATE BREAKING)	Ahmed Sawas	10
O-10	Potentials: CITN-10 pembrolizumab in MF/SS (LATE BREAKING)		10
15:35-15:50	Break & Poster Viewing		
15:50-16:50	Scientific Session P: Clinical Management and Challenging Cases		
	<i>Chairs: Kim, E, Hymes, Latkowski, Heald</i>		
◇	Introduction	Peter Heald	10
P-01	The Effect of Phototherapy on Progression to Tumors in Patients with Patch-Plaque Stage Mycosis Fungoides	Joyce W. Hoot	8
P-02	Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule	John Georgakopoulos	8
P-03	Eyelid involvement by MF/CTCL: a management challenge	Ellen J. Kim	8
P-04	The French Experience of Treatment of Cutaneous T Cell Lymphoma with Brentuximab Vedotin: A series of 32 Cases	Steve Mathieu	8
P-05	Evaluation of treatment in indolent and aggressive subgroups of folliculotropic mycosis fungoides	Suzanne van Santen	8
P-06	Treatment of early-stage folliculotropic mycosis fungoides: A single-center experience	Iris Amitay-Laish	8
16:50-17:00	Congress Conclusion & Closing Remarks	Martin Vermeer & Larisa Geskin	